Auteur

Dr Paul England

Senior Counsel – Knowledge

Read More
Auteur

Dr Paul England

Senior Counsel – Knowledge

Read More

30 avril 2020

Synapse - May 2020 – 4 de 5 Publications

Patents diary: April 2020

  • QUICK READ

English Court of Appeal clarifies the level of detail needed in an Arrow declaration

A new Court of Appeal decision concerning Arrow declarations, Mexichem UK Ltd v Honeywell International Inc [2020] EWCA Civ 473, the first instance decision of HHJ Hacon to refuse to strike out or grant summary judgment on an application for two Arrow declarations has been upheld. The declarations sought related to the use of certain refrigerants in the manufacture of products for mobile air-conditioning units; the claimant wanted to market these in the face of the defendant's pending applications in the EPO. 

The strike out was sought because the claimed declarations did not describe the product in actual production and neither were they based on a fully formulated product description.

The Court of Appeal states that it has a broad and flexible discretion to grant declaratory relief where it would serve a useful purpose, subject to sufficient clarity that it can be properly justiciable. That clarity requires the declaration to refer to specific features and combinations of features, but there is no threshold requirement that the party seeking an Arrow declaration has to have a fully formulated product description, and much less a product in actual production. The utility of the extent of generality or particularity of the declaration is a matter of degree to be assessed at trial. It is not correct to construe declarations as if they are patent claims, so that every conceivable product falling within the declaration is being declared to be obvious. 

The Court also comments that although the step-by-step analysis of obviousness had been held to be unfair in many cases (because of the risk of hindsight that it introduces), there is a class of case in which it can be relevant to consider each step in a putative series of steps taken by the skilled person and consider whether any of them individually, and cumulatively, was obvious (for which reference is made to the eight factor in the Supreme Court's Actavis v ICOS judgment).

Forum: English Court of Appeal
Date: 1 April 2020

Dans cette série

Synapse

COVID-19 and life sciences M&A

16 April 2020

par plusieurs auteurs

Synapse

COVID-19: healthcare and law

31 March 2020

Brevets et innovation

COVID-19 and public compulsory licensing of drugs in Europe

17 April 2020

par plusieurs auteurs

Synapse

Patents diary: April 2020

30 April 2020

par Dr Paul England

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Sciences de la vie et Santé

Personalised medicines and exclusive protection

19 juillet 2023

par Dr Paul England

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Three hot IP issues for the pharmaceutical industry

23 août 2022
Briefing

par Dr Paul England

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

UK medicines – Is the Northern Ireland Protocol now unsustainable?

14 octobre 2021
Quick read

par Dr Paul England

Cliquer ici pour en savoir plus